Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Angina (Angina Pectoris) Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Angina (Angina Pectoris) 9
Angina (Angina Pectoris) Therapeutics under Development by Companies 11
Angina (Angina Pectoris) Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Angina (Angina Pectoris) Therapeutics – Products under Development by Companies 18
Angina (Angina Pectoris) Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Angina (Angina Pectoris) Therapeutics Development 20
Baxter International Inc. 20
Merck & Co., Inc. 21
Ark Therapeutics Group plc 22
Astellas Pharma Inc. 23
Les Laboratoires Servier 24
HUYA Bioscience International, LLC 25
Diakron Pharmaceuticals, Inc. 26
Lacer, S.A. 27
Milestone Pharmaceuticals, Inc. 28
Angina (Angina Pectoris) – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
MK-0974 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
EG011 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
DP-3005 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
T89 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Hydroquinidine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Human Atrial Natriuretic Peptide - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Ranolazine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Capsaicin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
F 15845 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
HBI-3000 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
LA-8045 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Adult Autologous CD34+ Stem Cells - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
MSP-2017 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Angina (Angina Pectoris) Therapeutics – Drug Profile Updates 50
Angina (Angina Pectoris) Therapeutics – Discontinued Products 52
Angina (Angina Pectoris) Therapeutics - Dormant Products 53
Angina (Angina Pectoris) – Product Development Milestones 54
Featured News & Press Releases 54
May 16, 2012: Ark Completes Dose Ranging Phase I Section Of Refractory Angina Clinical Study 54
Apr 02, 2012: Ranbaxy’s Mohali SEZ Facility Begins Export Of Atorvastatin To US Market 54
Jan 26, 2012: Watson Confirms Court Stays Preliminary Injunction 55
Nov 07, 2011: Gilead Sciences And Cardiovascular Research Foundation Initiate Phase III Trial With Ranolazine in Chronic Angina Patients 55
Oct 08, 2011: Watson Provides Update On District Court Order Concerning Generic Version Of LOVENOX 56
Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients 56
Mar 18, 2011: Cytokinetics Announces Fundamental Research In Field Of Cardiac Myosin Activation Published In Journal Science 57
Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 58
Apr 01, 2010: Shionogi’s Nitrolingual Pumpspray is Available for Angina Pectoris Patients 58
Jan 28, 2010: First Refractory Angina Patient Treated With VEGF-D Shortform (EG011) In Phase I/IIa Trial 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62
List of Tables
Number of Products Under Development for Angina (Angina Pectoris), H2 2012 9
Products under Development for Angina (Angina Pectoris) – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Baxter International Inc., H2 2012 20
Merck & Co., Inc., H2 2012 21
Ark Therapeutics Group plc, H2 2012 22
Astellas Pharma Inc., H2 2012 23
Les Laboratoires Servier, H2 2012 24
HUYA Bioscience International, LLC, H2 2012 25
Diakron Pharmaceuticals, Inc., H2 2012 26
Lacer, S.A., H2 2012 27
Milestone Pharmaceuticals, Inc., H2 2012 28
Assessment by Monotherapy Products, H2 2012 29
Assessment by Combination Products, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 34
Angina (Angina Pectoris) Therapeutics – Drug Profile Updates 50
Angina (Angina Pectoris) Therapeutics – Discontinued Products 52
Angina (Angina Pectoris) Therapeutics – Dormant Products 53
List of Figures
Number of Products under Development for Angina (Angina Pectoris), H2 2012 9
Products under Development for Angina (Angina Pectoris) – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 29
Assessment by Combination Products, H2 2012 30
Assessment by Route of Administration, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Molecule Type, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 34